Cancer pain is the most common symptom in the patients which is caused by tumour pressing on other organs, nerves, or bones in the body. Chemotherapies also causes numbness and tingling sensations in patient’s hands or feet while radiotherapy results in skin irritation and redness. Cancer pain can be categorized into two types, including acute pain and chronic pain. The severity of pain depends upon the type of cancer, location of the cancer, stage of the cancer and presence of any nerve damage due to cancer or cancer treatment. The drug candidates in the pipeline of cancer pain include, but are not limited to, HP 3150 and Methadone. Some of the companies having a pipeline of cancer pain include Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Company, Limited, AstraZeneca plc, Depomed, Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.